Gout Drug Febuxostat (Uloric) Subject of FDA Safety Alert Gout Drug Febuxostat (Uloric) Subject of FDA Safety Alert

Preliminary data from a safety study show an increased risk for heart-related deaths with febuxostat compared with allopurinol in patients with gout, the FDA said.News Alerts
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news